Autologous Anti-CD19 Chimeric Antigen Receptor T-cells C-CAR011 clinical trials
- studies test it
- 5
- open now
- 0
- in phase 3
- 0
- first study started
- 2016
How each study uses Autologous Anti-CD19 Chimeric Antigen Receptor T-cells C-CAR011 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
5 studies that test it; most in 2017 (3)
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2017 | 3 |
| 2018 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 1
Shanghai AbelZeta Ltd. (4) · Peking University People's Hospital (1)
Studies
Open first, then newest update. How each study uses Autologous Anti-CD19 Chimeric Antigen Receptor T-cells C-CAR011 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- C-CAR011 Treatment in Subjects With ALL After HSCTStatus unknownNot applicablePeking University People's HospitalNCT03327285Written as C-CAR011How we know
- A Phase 1 Study Evaluating Safety and Efficacy of C-CAR011 Treatment in DLBCL SubjectsCompletedPhase 1Shanghai AbelZeta Ltd.NCT02976857Written as C-CAR-011How we know
- A Study Evaluating Safety and Efficacy of C-CAR011 in Subjects With B-NHLStatus unknownPhase 1Shanghai AbelZeta Ltd.NCT03299738Written as C-CAR011How we know
- Study of Safety and Efficacy of C-CAR011 in B-NHL PatientsStatus unknownPhase 1Shanghai AbelZeta Ltd.NCT03154775Written as C-CAR011How we know
- A Phase I Study Evaluating Safety and Efficacy of C-CAR011 Treatment in Adult Subjects With r/r CD19+B-ALLStatus unknownPhase 1Shanghai AbelZeta Ltd.NCT03018093Written as C-CAR-011How we know